FDA beat Mylan NV's expectations for the approval of its Copaxone generic, even though it appears that the agency may have missed the target date that had been set.
Mylan surprised investors late Oct. 3 when it announced the approval of its substitutable generic of Teva Pharmaceutical Industries...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?